The global market for Radionuclide Drug Conjugates (RDC) was valued at US$ 8965 million in the year 2024 and is projected to reach a revised size of US$ 14101 million by 2031, growing at a CAGR of 6.8% during the forecast period.

Radionuclide Drug Conjugates (RDC) Market

Radionuclide-conjugated drugs (RCDs) are complex molecules for precise targeted therapy and diagnosis, composed of three core elements: a targeting ligand, a linker, and a radionuclide. Their mechanism of action is similar to a "biologically guided miniature nuclear bomb": the targeting ligand specifically recognizes and binds to biomarkers highly expressed on the surface of diseased cells such as tumors; the linker ensures the stability of the entire molecule; and the radionuclide acts as the "warhead," accumulating at the target site and releasing ionizing radiation energy such as alpha and beta particles to destroy tumor cells from within, or releasing gamma/positron rays for highly sensitive molecular imaging diagnosis. This design achieves precise, "visualized" targeting of diseases and is a prime example of the deep integration of nuclear medicine and targeted drug technology.

The field of RCDs is experiencing explosive growth, with a broad and clear development prospect. Future trends will focus on: first, target diversification and drug iteration, with RDCs targeting new targets such as CLDN18.2 and FAP rapidly entering clinical trials, and the development of better ligands. Second, the advancement of treatment paradigms: the highly promising alpha radionuclide therapy holds the potential to conquer more complex and drug-resistant solid tumors, becoming a core next-generation treatment method. Third, the deep integration of diagnosis and treatment: patient stratification and personalized dosage regimens based on precise imaging will become standard procedures, greatly improving treatment efficiency and safety. Fourth, technological platform innovation: more stable connectivity technologies, prodrug strategies, and combination therapies will continuously expand its application boundaries. Overall, RDC is evolving from a "powerful tool" for a few specific cancer types into an indispensable precision diagnosis and treatment platform in oncology and even some non-oncology diseases.

This report aims to provide a comprehensive presentation of the global market for Radionuclide Drug Conjugates (RDC), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radionuclide Drug Conjugates (RDC).

The Radionuclide Drug Conjugates (RDC) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Radionuclide Drug Conjugates (RDC) market comprehensively. Regional market sizes, concerning products by Targeted Ligands, by Application, by Therapeutic Purposes and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Radionuclide Drug Conjugates (RDC) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Targeted Ligands, by Application, and by regions.

Market Segmentation

Scope of Radionuclide Drug Conjugates (RDC) Market Report

Report Metric	Details
Report Name	Radionuclide Drug Conjugates (RDC) Market
Accounted market size in year	US$ 8965 million
Forecasted market size in 2031	US$ 14101 million
CAGR	6.8%
Base Year	year
Forecasted years	2026 - 2031
Segment by Targeted Ligands	Small molecules Peptides Antibodies
Segment by Therapeutic Purposes	Therapeutic RDCs Diagnostic RDCs
Segment by Decay Types	Alpha Nuclide RDCs Beta Nuclide RDCs
Segment by Application	Prostate Cancer Neuroendocrine Tumors Liver Cancer Kidney Cancer Bone Metastases Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Eli Lilly, Bayer, Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, China Isotope & Radiation Corporation, Dongcheng Pharmaceutical, Grand Pharmaceutical Group, Hengrui Medicine, Bivision, SmartNuclide, Hexin (Suzhou) Pharmaceutical Technology Co., Ltd., Xiantong Pharmaceutical, Full-Life Technologies, Nuoyu Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Targeted Ligands, by Application, by Therapeutic Purposes etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radionuclide Drug Conjugates (RDC) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Targeted Ligands, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Radionuclide Drug Conjugates (RDC) Market growing?

Ans: The Radionuclide Drug Conjugates (RDC) Market witnessing a CAGR of 6.8% during the forecast period 2026-2031.

What is the Radionuclide Drug Conjugates (RDC) Market size in 2031?

Ans: The Radionuclide Drug Conjugates (RDC) Market size in 2031 will be US$ 14101 million.

Who are the main players in the Radionuclide Drug Conjugates (RDC) Market report?

Ans: The main players in the Radionuclide Drug Conjugates (RDC) Market are Novartis, Eli Lilly, Bayer, Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, China Isotope & Radiation Corporation, Dongcheng Pharmaceutical, Grand Pharmaceutical Group, Hengrui Medicine, Bivision, SmartNuclide, Hexin (Suzhou) Pharmaceutical Technology Co., Ltd., Xiantong Pharmaceutical, Full-Life Technologies, Nuoyu Pharmaceutical

What are the Application segmentation covered in the Radionuclide Drug Conjugates (RDC) Market report?

Ans: The Applications covered in the Radionuclide Drug Conjugates (RDC) Market report are Prostate Cancer, Neuroendocrine Tumors, Liver Cancer, Kidney Cancer, Bone Metastases, Others

What are the Type segmentation covered in the Radionuclide Drug Conjugates (RDC) Market report?

Ans: The Types covered in the Radionuclide Drug Conjugates (RDC) Market report are Alpha Nuclide RDCs, Beta Nuclide RDCs

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Targeted Ligands

1.2.1 Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Targeted Ligands: 2020 VS 2024 VS 2031

1.2.2 Small molecules

1.2.3 Peptides

1.2.4 Antibodies

1.3 Market by Therapeutic Purposes

1.3.1 Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Therapeutic Purposes: 2020 VS 2024 VS 2031

1.3.2 Therapeutic RDCs

1.3.3 Diagnostic RDCs

1.4 Market by Decay Types

1.4.1 Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Decay Types: 2020 VS 2024 VS 2031

1.4.2 Alpha Nuclide RDCs

1.4.3 Beta Nuclide RDCs

1.5 Market by Application

1.5.1 Global Radionuclide Drug Conjugates (RDC) Market Growth by Application: 2020 VS 2024 VS 2031

1.5.2 Prostate Cancer

1.5.3 Neuroendocrine Tumors

1.5.4 Liver Cancer

1.5.5 Kidney Cancer

1.5.6 Bone Metastases

1.5.7 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Radionuclide Drug Conjugates (RDC) Market Perspective (2020-2031)

2.2 Global Radionuclide Drug Conjugates (RDC) Growth Trends by Region

2.2.1 Global Radionuclide Drug Conjugates (RDC) Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Radionuclide Drug Conjugates (RDC) Historic Market Size by Region (2020-2025)

2.2.3 Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Region (2026-2031)

2.3 Radionuclide Drug Conjugates (RDC) Market Dynamics

2.3.1 Radionuclide Drug Conjugates (RDC) Industry Trends

2.3.2 Radionuclide Drug Conjugates (RDC) Market Drivers

2.3.3 Radionuclide Drug Conjugates (RDC) Market Challenges

2.3.4 Radionuclide Drug Conjugates (RDC) Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Radionuclide Drug Conjugates (RDC) Players by Revenue

3.1.1 Global Top Radionuclide Drug Conjugates (RDC) Players by Revenue (2020-2025)

3.1.2 Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Players (2020-2025)

3.2 Global Top Radionuclide Drug Conjugates (RDC) Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Radionuclide Drug Conjugates (RDC) Revenue

3.4 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio

3.4.1 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Radionuclide Drug Conjugates (RDC) Revenue in 2024

3.5 Global Key Players of Radionuclide Drug Conjugates (RDC) Head office and Area Served

3.6 Global Key Players of Radionuclide Drug Conjugates (RDC), Product and Application

3.7 Global Key Players of Radionuclide Drug Conjugates (RDC), Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Radionuclide Drug Conjugates (RDC) Breakdown Data by Targeted Ligands

4.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Targeted Ligands (2020-2025)

4.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Targeted Ligands (2026-2031)

5 Radionuclide Drug Conjugates (RDC) Breakdown Data by Application

5.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Application (2020-2025)

5.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)

6.2 North America Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025)

6.4 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)

7.2 Europe Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025)

7.4 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)

8.2 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2020-2025)

8.4 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)

9.2 Latin America Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025)

9.4 Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size (2020-2031)

10.2 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025)

10.4 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Radionuclide Drug Conjugates (RDC) Introduction

11.1.4 Novartis Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.1.5 Novartis Recent Development

11.2 Eli Lilly

11.2.1 Eli Lilly Company Details

11.2.2 Eli Lilly Business Overview

11.2.3 Eli Lilly Radionuclide Drug Conjugates (RDC) Introduction

11.2.4 Eli Lilly Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.2.5 Eli Lilly Recent Development

11.3 Bayer

11.3.1 Bayer Company Details

11.3.2 Bayer Business Overview

11.3.3 Bayer Radionuclide Drug Conjugates (RDC) Introduction

11.3.4 Bayer Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.3.5 Bayer Recent Development

11.4 Johnson & Johnson

11.4.1 Johnson & Johnson Company Details

11.4.2 Johnson & Johnson Business Overview

11.4.3 Johnson & Johnson Radionuclide Drug Conjugates (RDC) Introduction

11.4.4 Johnson & Johnson Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.4.5 Johnson & Johnson Recent Development

11.5 Bristol-Myers Squibb

11.5.1 Bristol-Myers Squibb Company Details

11.5.2 Bristol-Myers Squibb Business Overview

11.5.3 Bristol-Myers Squibb Radionuclide Drug Conjugates (RDC) Introduction

11.5.4 Bristol-Myers Squibb Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.5.5 Bristol-Myers Squibb Recent Development

11.6 AstraZeneca

11.6.1 AstraZeneca Company Details

11.6.2 AstraZeneca Business Overview

11.6.3 AstraZeneca Radionuclide Drug Conjugates (RDC) Introduction

11.6.4 AstraZeneca Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.6.5 AstraZeneca Recent Development

11.7 China Isotope & Radiation Corporation

11.7.1 China Isotope & Radiation Corporation Company Details

11.7.2 China Isotope & Radiation Corporation Business Overview

11.7.3 China Isotope & Radiation Corporation Radionuclide Drug Conjugates (RDC) Introduction

11.7.4 China Isotope & Radiation Corporation Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.7.5 China Isotope & Radiation Corporation Recent Development

11.8 Dongcheng Pharmaceutical

11.8.1 Dongcheng Pharmaceutical Company Details

11.8.2 Dongcheng Pharmaceutical Business Overview

11.8.3 Dongcheng Pharmaceutical Radionuclide Drug Conjugates (RDC) Introduction

11.8.4 Dongcheng Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.8.5 Dongcheng Pharmaceutical Recent Development

11.9 Grand Pharmaceutical Group

11.9.1 Grand Pharmaceutical Group Company Details

11.9.2 Grand Pharmaceutical Group Business Overview

11.9.3 Grand Pharmaceutical Group Radionuclide Drug Conjugates (RDC) Introduction

11.9.4 Grand Pharmaceutical Group Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.9.5 Grand Pharmaceutical Group Recent Development

11.10 Hengrui Medicine

11.10.1 Hengrui Medicine Company Details

11.10.2 Hengrui Medicine Business Overview

11.10.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Introduction

11.10.4 Hengrui Medicine Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.10.5 Hengrui Medicine Recent Development

11.11 Bivision

11.11.1 Bivision Company Details

11.11.2 Bivision Business Overview

11.11.3 Bivision Radionuclide Drug Conjugates (RDC) Introduction

11.11.4 Bivision Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.11.5 Bivision Recent Development

11.12 SmartNuclide

11.12.1 SmartNuclide Company Details

11.12.2 SmartNuclide Business Overview

11.12.3 SmartNuclide Radionuclide Drug Conjugates (RDC) Introduction

11.12.4 SmartNuclide Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.12.5 SmartNuclide Recent Development

11.13 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.

11.13.1 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Details

11.13.2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview

11.13.3 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Introduction

11.13.4 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.13.5 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Development

11.14 Xiantong Pharmaceutical

11.14.1 Xiantong Pharmaceutical Company Details

11.14.2 Xiantong Pharmaceutical Business Overview

11.14.3 Xiantong Pharmaceutical Radionuclide Drug Conjugates (RDC) Introduction

11.14.4 Xiantong Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.14.5 Xiantong Pharmaceutical Recent Development

11.15 Full-Life Technologies

11.15.1 Full-Life Technologies Company Details

11.15.2 Full-Life Technologies Business Overview

11.15.3 Full-Life Technologies Radionuclide Drug Conjugates (RDC) Introduction

11.15.4 Full-Life Technologies Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.15.5 Full-Life Technologies Recent Development

11.16 Nuoyu Pharmaceutical

11.16.1 Nuoyu Pharmaceutical Company Details

11.16.2 Nuoyu Pharmaceutical Business Overview

11.16.3 Nuoyu Pharmaceutical Radionuclide Drug Conjugates (RDC) Introduction

11.16.4 Nuoyu Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

11.16.5 Nuoyu Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Bayer

Novartis

Hengrui Medicine

China Isotope & Radiation Corporation

Dongcheng Pharmaceutical

Grand Pharmaceutical Group

Bivision

SmartNuclide

Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.

Xiantong Pharmaceutical

Full-Life Technologies

Nuoyu Pharmaceutical

List of Tables

Table 1. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Targeted Ligands (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Small molecules

Table 3. Key Players of Peptides

Table 4. Key Players of Antibodies

Table 5. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Therapeutic Purposes (US$ Million): 2020 VS 2024 VS 2031

Table 6. Key Players of Therapeutic RDCs

Table 7. Key Players of Diagnostic RDCs

Table 8. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Decay Types (US$ Million): 2020 VS 2024 VS 2031

Table 9. Key Players of Alpha Nuclide RDCs

Table 10. Key Players of Beta Nuclide RDCs

Table 11. Global Radionuclide Drug Conjugates (RDC) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 12. Global Radionuclide Drug Conjugates (RDC) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 13. Global Radionuclide Drug Conjugates (RDC) Market Size by Region (2020-2025) & (US$ Million)

Table 14. Global Radionuclide Drug Conjugates (RDC) Market Share by Region (2020-2025)

Table 15. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 16. Global Radionuclide Drug Conjugates (RDC) Market Share by Region (2026-2031)

Table 17. Radionuclide Drug Conjugates (RDC) Market Trends

Table 18. Radionuclide Drug Conjugates (RDC) Market Drivers

Table 19. Radionuclide Drug Conjugates (RDC) Market Challenges

Table 20. Radionuclide Drug Conjugates (RDC) Market Restraints

Table 21. Global Radionuclide Drug Conjugates (RDC) Revenue by Players (2020-2025) & (US$ Million)

Table 22. Global Radionuclide Drug Conjugates (RDC) Market Share by Players (2020-2025)

Table 23. Global Top Radionuclide Drug Conjugates (RDC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radionuclide Drug Conjugates (RDC) as of 2024)

Table 24. Ranking of Global Top Radionuclide Drug Conjugates (RDC) Companies by Revenue (US$ Million) in 2024

Table 25. Global 5 Largest Players Market Share by Radionuclide Drug Conjugates (RDC) Revenue (CR5 and HHI) & (2020-2025)

Table 26. Global Key Players of Radionuclide Drug Conjugates (RDC), Headquarters and Area Served

Table 27. Global Key Players of Radionuclide Drug Conjugates (RDC), Product and Application

Table 28. Global Key Players of Radionuclide Drug Conjugates (RDC), Date of Enter into This Industry

Table 29. Mergers & Acquisitions, Expansion Plans

Table 30. Global Radionuclide Drug Conjugates (RDC) Market Size by Targeted Ligands (2020-2025) & (US$ Million)

Table 31. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Targeted Ligands (2020-2025)

Table 32. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Targeted Ligands (2026-2031) & (US$ Million)

Table 33. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Targeted Ligands (2026-2031)

Table 34. Global Radionuclide Drug Conjugates (RDC) Market Size by Application (2020-2025) & (US$ Million)

Table 35. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Application (2020-2025)

Table 36. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 37. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Application (2026-2031)

Table 38. North America Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 39. North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025) & (US$ Million)

Table 40. North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031) & (US$ Million)

Table 41. Europe Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025) & (US$ Million)

Table 43. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031) & (US$ Million)

Table 44. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 45. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2020-2025) & (US$ Million)

Table 46. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2026-2031) & (US$ Million)

Table 47. Latin America Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025) & (US$ Million)

Table 49. Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031) & (US$ Million)

Table 50. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 51. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2020-2025) & (US$ Million)

Table 52. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2026-2031) & (US$ Million)

Table 53. Novartis Company Details

Table 54. Novartis Business Overview

Table 55. Novartis Radionuclide Drug Conjugates (RDC) Product

Table 56. Novartis Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 57. Novartis Recent Development

Table 58. Eli Lilly Company Details

Table 59. Eli Lilly Business Overview

Table 60. Eli Lilly Radionuclide Drug Conjugates (RDC) Product

Table 61. Eli Lilly Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 62. Eli Lilly Recent Development

Table 63. Bayer Company Details

Table 64. Bayer Business Overview

Table 65. Bayer Radionuclide Drug Conjugates (RDC) Product

Table 66. Bayer Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 67. Bayer Recent Development

Table 68. Johnson & Johnson Company Details

Table 69. Johnson & Johnson Business Overview

Table 70. Johnson & Johnson Radionuclide Drug Conjugates (RDC) Product

Table 71. Johnson & Johnson Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 72. Johnson & Johnson Recent Development

Table 73. Bristol-Myers Squibb Company Details

Table 74. Bristol-Myers Squibb Business Overview

Table 75. Bristol-Myers Squibb Radionuclide Drug Conjugates (RDC) Product

Table 76. Bristol-Myers Squibb Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 77. Bristol-Myers Squibb Recent Development

Table 78. AstraZeneca Company Details

Table 79. AstraZeneca Business Overview

Table 80. AstraZeneca Radionuclide Drug Conjugates (RDC) Product

Table 81. AstraZeneca Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 82. AstraZeneca Recent Development

Table 83. China Isotope & Radiation Corporation Company Details

Table 84. China Isotope & Radiation Corporation Business Overview

Table 85. China Isotope & Radiation Corporation Radionuclide Drug Conjugates (RDC) Product

Table 86. China Isotope & Radiation Corporation Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 87. China Isotope & Radiation Corporation Recent Development

Table 88. Dongcheng Pharmaceutical Company Details

Table 89. Dongcheng Pharmaceutical Business Overview

Table 90. Dongcheng Pharmaceutical Radionuclide Drug Conjugates (RDC) Product

Table 91. Dongcheng Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 92. Dongcheng Pharmaceutical Recent Development

Table 93. Grand Pharmaceutical Group Company Details

Table 94. Grand Pharmaceutical Group Business Overview

Table 95. Grand Pharmaceutical Group Radionuclide Drug Conjugates (RDC) Product

Table 96. Grand Pharmaceutical Group Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 97. Grand Pharmaceutical Group Recent Development

Table 98. Hengrui Medicine Company Details

Table 99. Hengrui Medicine Business Overview

Table 100. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product

Table 101. Hengrui Medicine Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 102. Hengrui Medicine Recent Development

Table 103. Bivision Company Details

Table 104. Bivision Business Overview

Table 105. Bivision Radionuclide Drug Conjugates (RDC) Product

Table 106. Bivision Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 107. Bivision Recent Development

Table 108. SmartNuclide Company Details

Table 109. SmartNuclide Business Overview

Table 110. SmartNuclide Radionuclide Drug Conjugates (RDC) Product

Table 111. SmartNuclide Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 112. SmartNuclide Recent Development

Table 113. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Details

Table 114. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Business Overview

Table 115. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product

Table 116. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 117. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Development

Table 118. Xiantong Pharmaceutical Company Details

Table 119. Xiantong Pharmaceutical Business Overview

Table 120. Xiantong Pharmaceutical Radionuclide Drug Conjugates (RDC) Product

Table 121. Xiantong Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 122. Xiantong Pharmaceutical Recent Development

Table 123. Full-Life Technologies Company Details

Table 124. Full-Life Technologies Business Overview

Table 125. Full-Life Technologies Radionuclide Drug Conjugates (RDC) Product

Table 126. Full-Life Technologies Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 127. Full-Life Technologies Recent Development

Table 128. Nuoyu Pharmaceutical Company Details

Table 129. Nuoyu Pharmaceutical Business Overview

Table 130. Nuoyu Pharmaceutical Radionuclide Drug Conjugates (RDC) Product

Table 131. Nuoyu Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2020-2025) & (US$ Million)

Table 132. Nuoyu Pharmaceutical Recent Development

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Radionuclide Drug Conjugates (RDC) Picture

Figure 2. Global Radionuclide Drug Conjugates (RDC) Market Size Comparison by Targeted Ligands (2020-2031) & (US$ Million)

Figure 3. Global Radionuclide Drug Conjugates (RDC) Market Share by Targeted Ligands: 2024 VS 2031

Figure 4. Small molecules Features

Figure 5. Peptides Features

Figure 6. Antibodies Features

Figure 7. Global Radionuclide Drug Conjugates (RDC) Market Size Comparison by Therapeutic Purposes (2020-2031) & (US$ Million)

Figure 8. Therapeutic RDCs Features

Figure 9. Diagnostic RDCs Features

Figure 10. Global Radionuclide Drug Conjugates (RDC) Market Size Comparison by Decay Types (2020-2031) & (US$ Million)

Figure 11. Alpha Nuclide RDCs Features

Figure 12. Beta Nuclide RDCs Features

Figure 13. Global Radionuclide Drug Conjugates (RDC) Market Size by Application (2020-2031) & (US$ Million)

Figure 14. Global Radionuclide Drug Conjugates (RDC) Market Share by Application: 2024 VS 2031

Figure 15. Prostate Cancer Case Studies

Figure 16. Neuroendocrine Tumors Case Studies

Figure 17. Liver Cancer Case Studies

Figure 18. Kidney Cancer Case Studies

Figure 19. Bone Metastases Case Studies

Figure 20. Others Case Studies

Figure 21. Radionuclide Drug Conjugates (RDC) Report Years Considered

Figure 22. Global Radionuclide Drug Conjugates (RDC) Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 23. Global Radionuclide Drug Conjugates (RDC) Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 24. Global Radionuclide Drug Conjugates (RDC) Market Share by Region: 2024 VS 2031

Figure 25. Global Radionuclide Drug Conjugates (RDC) Market Share by Players in 2024

Figure 26. Global Radionuclide Drug Conjugates (RDC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 27. The Top 10 and 5 Players Market Share by Radionuclide Drug Conjugates (RDC) Revenue in 2024

Figure 28. North America Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. North America Radionuclide Drug Conjugates (RDC) Market Share by Country (2020-2031)

Figure 30. United States Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Canada Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Europe Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Europe Radionuclide Drug Conjugates (RDC) Market Share by Country (2020-2031)

Figure 34. Germany Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. France Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. U.K. Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Italy Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Russia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Ireland Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Share by Region (2020-2031)

Figure 42. China Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Japan Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. South Korea Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. India Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Australia & New Zealand Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Latin America Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Latin America Radionuclide Drug Conjugates (RDC) Market Share by Country (2020-2031)

Figure 50. Mexico Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Brazil Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Share by Country (2020-2031)

Figure 54. Israel Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. Saudi Arabia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 56. UAE Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 57. Novartis Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 58. Eli Lilly Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 59. Bayer Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 60. Johnson & Johnson Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 62. AstraZeneca Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 63. China Isotope & Radiation Corporation Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 64. Dongcheng Pharmaceutical Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 65. Grand Pharmaceutical Group Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 66. Hengrui Medicine Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 67. Bivision Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 68. SmartNuclide Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 69. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 70. Xiantong Pharmaceutical Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 71. Full-Life Technologies Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 72. Nuoyu Pharmaceutical Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2020-2025)

Figure 73. Bottom-up and Top-down Approaches for This Report

Figure 74. Data Triangulation

Figure 75. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Targeted Radionuclide Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Radiopharmaceutical for Nuclear Medicine Market Research Report 2024

Global Nuclear Radiopharmaceutical Market Insights Forecast to 2030

Radioisotope Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Radiology Drug Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Radiotheranostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Nuclear Medicine Imaging Agents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oncology Radiopharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Radioactive Isotopes Market Research Report 2025

Radiopharmaceutical Synthesizers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Radioactive Medical Isotopes Market Research Report 2024

Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Research Report 2024

Global Radioisotopes in Industry Market Research Report 2025

Nuclear Medicine Radiopharmaceutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Radioligand Therapy Market Research Report 2025

Isotopes for Nuclear Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Medical Radioactive Isotopes Market Research Report 2025

Rapid Diagnostic Test RDTs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Radiopharmaceutical Solutions Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions